Brokerages Set Dyne Therapeutics, Inc. (NASDAQ:DYN) Price Target at $34.17

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have received an average rating of “Moderate Buy” from the fifteen research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $34.4167.

Several research firms recently weighed in on DYN. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Friday, July 17th. Sanford C. Bernstein lifted their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. TD Cowen began coverage on Dyne Therapeutics in a research note on Friday, June 26th. They set a “buy” rating for the company. Evercore set a $33.00 target price on Dyne Therapeutics in a report on Friday, May 15th. Finally, Wall Street Zen downgraded Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday.

Insider Buying and Selling

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 480,240 shares of the firm’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $22.79, for a total value of $10,944,669.60. Following the transaction, the director owned 875,912 shares in the company, valued at approximately $19,962,034.48. This trade represents a 35.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders acquired 9,000 shares of company stock valued at $156,800 and sold 1,665,542 shares valued at $36,321,576. Corporate insiders own 9.46% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds have recently modified their holdings of the business. Hilton Head Capital Partners LLC purchased a new position in shares of Dyne Therapeutics in the first quarter worth about $26,000. Strs Ohio acquired a new position in Dyne Therapeutics during the fourth quarter worth about $51,000. Aster Capital Management DIFC Ltd purchased a new stake in Dyne Therapeutics during the 4th quarter valued at about $84,000. Steward Partners Investment Advisory LLC grew its stake in Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after acquiring an additional 2,465 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in Dyne Therapeutics by 275.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after acquiring an additional 7,697 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Stock Performance

NASDAQ:DYN opened at $25.18 on Tuesday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 19.92 and a current ratio of 12.02. The company has a fifty day moving average of $21.24 and a two-hundred day moving average of $18.87. The stock has a market capitalization of $4.70 billion, a PE ratio of -7.56 and a beta of 1.06. Dyne Therapeutics has a fifty-two week low of $9.57 and a fifty-two week high of $26.26.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.33). As a group, research analysts forecast that Dyne Therapeutics will post -3.28 earnings per share for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.